Phase 2 N=9 The Sleep, Liver Evaluation and Effective Pressure Study
Non Alcoholic Fatty Liver Disease · Obstructive Sleep Apnea
Primary: Cross Sectional Analysis of NAFLD Versus Sleep Apnea Severity Indices (AHI)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=222 PF-06372865 In Subjects With Chronic Low Back Pain
Chronic Low Back Pain
Primary: Change From Baseline in Daily Low Back Pain Intensity (LBPI) Score as Measured by an 11-point Numeric Rating Scale (NRS) at Week 4 — -1.19; -1.03; -1.45 units on a scale
Phase 2 N=31 Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Primary: Objective Tumor Response — 0.071 proportion
Phase 2 N=48 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer
Brain and Central Nervous System Tumors · Extragonadal Germ Cell Tumor · Ovarian Cancer
Primary: Progression-free Survival — 11.8 Months
Phase 2 N=6 Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease
ISCHEMIC CARDIOMYOPATHY
Primary: COMPARISON OF MYOCARDIAL INFARCTION SIZE MEASUREMENTS USING INVESTIGATIONAL MANGANESE-ENHANCED MRI (MEMRI) OR DELAYED GADOLINIUM ENHANCED MRI (DEMRI) — 41; 18.25…
Phase 2 N=14 An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders
Autism · Asperger's Disorder · Pervasive Developmental Disorder
Primary: Clinical Global Impressions-Improvement — 1.8 units on a scale
Phase 2 N=18 The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial
Spinal Ischemia · Stroke · Neuroprotection
Primary: Death or Neurologic Disability, Defined as an National Institutes of Health Stroke Scale (NIHSS)>4 or American Spinal Injury Association (ASIA) Lower Extermity Motor…
Phase 2 N=1,457 A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee
Osteoarthritis
Primary: Rate of Progression of Joint Space Narrowing — -0.101; -0.125; -0.109 mm/year — p=0.508770
Phase 2 N=27 Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)
Rheumatoid Arthritis
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 17; 9; 6; 2 Participants
Phase 2 N=56 Multi-Center Pre-Bariatric Weight Loss Study
Obesity
Primary: Percent Excess Weight Loss (%EWL) at Week 12 — 11.9; 2.7 Percentage of Excess Weight Loss
Phase 2 N=17 Varenicline In-Patient Study
Smoking Cessation
Primary: 7 Day Point Prevalence Abstinence From All Forms of Tobacco — 2; 2 participants
Phase 2 N=198 Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis
Psoriasis
Primary: Dose-response Efficacy Profile of AMG 827 Compared With Placebo as Measured by the Percent Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at…
Phase 2 N=400 Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants
Influenza Infection
Primary: Seroconversion Rate of Hemagglutination Inhibition (HI) Antibody Titer (Egg-Derived Antigen) — 47.7; 46.0; 31.2; 36.0 percentage of participants
Phase 2 N=24 Safety and Pharmacokinetics of Kovacaine Nasal Spray (24 Hour Blood Collection)
Anesthesia
Primary: Cmax of Oxymetazoline and PBBA — 1.79; 465 ng/mL
Phase 2 N=30 Open-Label Study of Efficacy and Recommended Dose of Kovacaine Mist for Anesthetizing Maxillary Teeth
Anesthesia
Primary: The Proportion of Subjects Receiving Kovacaine Mist Who do Not Require Rescue Anesthesia During the Operative Dental Procedure — 10; 7; 8 participants